Thus, providing hope for the treatment of metastatic or refractory osteosarcoma where clinical trials of anti-HER2 trastuzumab or anti-GD2 dinutuximab and ICI were unsuccessful. This evidence concerns the gene ERBB2 and osteosarcoma.